Valuation: Xencor, Inc.

Market Cap 1.11B 972M 893M 833M 1.58B 106B 1.6B 10.73B 4.17B 52.05B 4.17B 4.08B 179B P/E 2026 *
-3.88x
P/E 2027 * -4.64x
Enterprise Value 1.11B 972M 893M 833M 1.58B 106B 1.6B 10.73B 4.17B 52.05B 4.17B 4.08B 179B EV / Sales 2026 *
15.2x
EV / Sales 2027 * 10.1x
Free-Float
98.82%
Yield 2026 *
-
Yield 2027 * -
1 day-2.47%
1 week-0.33%
Current month-6.83%
1 month+31.35%
3 months+17.10%
6 months+0.54%
Current year-2.02%
1 week 14.69
Extreme 14.69
16.8
1 month 11.2
Extreme 11.2
16.8
Current year 10.38
Extreme 10.375
16.8
1 year 6.92
Extreme 6.92
18.69
3 years 6.92
Extreme 6.92
27.24
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 31/01/2005
Director of Finance/CFO 48 08/04/2024
Chief Tech/Sci/R&D Officer 61 30/09/2006
Director TitleAgeSince
Director/Board Member 55 31/07/1997
Director/Board Member 58 24/07/2014
Director/Board Member 72 17/03/2015
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Director

-6,843 0.0092%
06-14Sell

Director

-5,064 0.0068%
06-14Sell

Director

-5,474 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
-2.47%-0.33%+78.15%-39.76% 1.11B
+0.68%+5.92%+80.45%+137.78% 58.73B
+2.32%+5.03%+75.51%+94.88% 53.92B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 18.8B
-0.29%+9.78%+44.62%-27.94% 17.61B
0.00%+20.78%+178.93%+360.74% 16.25B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 13.9B
Average +2.34%+6.62%+56.99%+127.17% 24.32B
Weighted average by Cap. +2.42%+5.51%+59.15%+137.62%

Financials

2026 *2027 *
Net sales 73.03M 63.84M 58.67M 54.69M 104M 6.95B 105M 704M 274M 3.42B 274M 268M 11.78B 110M 96.55M 88.73M 82.71M 157M 10.52B 159M 1.07B 414M 5.17B 415M 406M 17.81B
Net income -307M -268M -246M -230M -436M -29.21B -442M -2.96B -1.15B -14.36B -1.15B -1.13B -49.48B -288M -252M -231M -216M -409M -27.41B -415M -2.78B -1.08B -13.47B -1.08B -1.06B -46.43B
Net Debt - -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
02/07/26 US$15.00 -2.47% 919,419
01/07/26 US$15.38 -4.47% 1,020,105
30/06/26 US$16.10 +3.21% 1,500,302
29/06/26 US$15.60 +3.65% 749,505
26/06/26 US$15.05 +2.10% 1,981,661
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
15.00USD
Average target price
28.50USD
Spread / Average Target
+90.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock